Healthcare Sales & Marketing Network News: Xibrom

Searching News Database: Xibrom

HSMN NewsFeed - 13 Oct 2011
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 17 Nov 2010
ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 26 Sep 2008
ISTA Pharmaceuticals Receives $65 Million Funding Commitment
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Nov 2007
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 8 Feb 2007
ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 30 May 2006
ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 4 May 2006
ISTA Pharmaceuticals(R) Announces Study Indicating Twice-Daily Dosing of Xibrom(TM) as Equivalent to Four Times a Day of Other Treatments
Biopharmaceuticals Ophthalmology

Return to NewsFeed

Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 6 additional stories matching:
Xibrom
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.